Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SGN-CD47M
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SGN-CD47M is an antibody-drug conjugate (ADC) developed for the treatment of solid tumors. It consists of a humanized monoclonal IgG1 antibody targeting the cell surface antigen CD47, which is overexpressed on many tumor cells and acts as a "don't eat me" signal to evade immune surveillance. The antibody is linked to novel masking peptides via protease-cleavable linkers that are selectively activated in the tumor microenvironment, aiming to reduce systemic toxicity and enhance antitumor activity. This design allows for preferential activation within tumors, potentially improving tolerability compared to unmasked anti-CD47 antibodies. The drug was initially developed by Seagen and entered phase 1 clinical trials for various solid tumors but has since been discontinued[2][5][6].
- Brand names
- SGN-CD47MSGN-CD-47MSGN-CD 47M
- Other names
- anti-CD47 ADC SGN-CD47Manti-CD-47 ADC SGN-CD47Manti-CD 47 ADC SGN-CD47M
02
Targets
CD47 (Cluster of Differentiation 47)
Beyond the preview
Go deeper on SGN-CD47M.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SGN-CD47M.